A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

Gian Domenico Borasio, W. Robberecht, P. N. Leigh, J. Emile, R. J. Guiloff, F. Jerusalem, V. Silani, P. E. Vos, J. H J Wokke, T. Dobbins

Research output: Contribution to journalArticle

286 Citations (Scopus)

Abstract

To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

Original languageEnglish
Pages (from-to)583-586
Number of pages4
JournalNeurology
Volume51
Issue number2
Publication statusPublished - Aug 1998

Fingerprint

Amyotrophic Lateral Sclerosis
Insulin-Like Growth Factor I
Placebos
Disease Progression
Outcome Assessment (Health Care)
Safety
Therapeutics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Borasio, G. D., Robberecht, W., Leigh, P. N., Emile, J., Guiloff, R. J., Jerusalem, F., ... Dobbins, T. (1998). A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology, 51(2), 583-586.

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. / Borasio, Gian Domenico; Robberecht, W.; Leigh, P. N.; Emile, J.; Guiloff, R. J.; Jerusalem, F.; Silani, V.; Vos, P. E.; Wokke, J. H J; Dobbins, T.

In: Neurology, Vol. 51, No. 2, 08.1998, p. 583-586.

Research output: Contribution to journalArticle

Borasio, GD, Robberecht, W, Leigh, PN, Emile, J, Guiloff, RJ, Jerusalem, F, Silani, V, Vos, PE, Wokke, JHJ & Dobbins, T 1998, 'A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis', Neurology, vol. 51, no. 2, pp. 583-586.
Borasio GD, Robberecht W, Leigh PN, Emile J, Guiloff RJ, Jerusalem F et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology. 1998 Aug;51(2):583-586.
Borasio, Gian Domenico ; Robberecht, W. ; Leigh, P. N. ; Emile, J. ; Guiloff, R. J. ; Jerusalem, F. ; Silani, V. ; Vos, P. E. ; Wokke, J. H J ; Dobbins, T. / A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. In: Neurology. 1998 ; Vol. 51, No. 2. pp. 583-586.
@article{9701045142cd4285aca82b37b3725f04,
title = "A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis",
abstract = "To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.",
author = "Borasio, {Gian Domenico} and W. Robberecht and Leigh, {P. N.} and J. Emile and Guiloff, {R. J.} and F. Jerusalem and V. Silani and Vos, {P. E.} and Wokke, {J. H J} and T. Dobbins",
year = "1998",
month = "8",
language = "English",
volume = "51",
pages = "583--586",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis

AU - Borasio, Gian Domenico

AU - Robberecht, W.

AU - Leigh, P. N.

AU - Emile, J.

AU - Guiloff, R. J.

AU - Jerusalem, F.

AU - Silani, V.

AU - Vos, P. E.

AU - Wokke, J. H J

AU - Dobbins, T.

PY - 1998/8

Y1 - 1998/8

N2 - To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

AB - To test the safety and efficacy of recombinant human insulin-like growth factor-I (rhIGF-I) in ALS, 183 patients from eight European centers were randomized to receive double-blind placebo (n = 59) or rhIGF-I 0.1 mg/kg/day (n = 124) subcutaneously for 9 months. At study completion, the primary efficacy outcome measure (change in disease progression as assessed by the Appel ALS rating scale) showed no significant difference between treatment groups. RhIGF-I appeared to be safe and well-tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0031722582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031722582&partnerID=8YFLogxK

M3 - Article

C2 - 9710040

AN - SCOPUS:0031722582

VL - 51

SP - 583

EP - 586

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 2

ER -